Director at Beta Bionics (BBNX) receives 16,965-share equity award

Rhea-AI Filing Summary

MICHEL GERARD J reported acquisition or exercise transactions in this Form 4 filing.

Beta Bionics, Inc. director MICHEL GERARD J received an equity grant of 16,965 shares of Common Stock on May 21, 2026. The award is structured as a restricted stock unit grant under the company’s 2025 Equity Incentive Plan and was issued at no cash cost, raising his direct holdings to 33,509 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MICHEL GERARD J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,965	$0.00	--

Holdings After Transaction: Common Stock — 33,509 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 16,965 shares Holdings after grant: 33,509 shares Grant price per share: $0.0000 per share

3 metrics

Equity grant size 16,965 shares Restricted stock unit award on May 21, 2026

Holdings after grant 33,509 shares Total Common Stock directly held post-transaction

Grant price per share $0.0000 per share Reported transaction price for RSU award

Key Terms

restricted stock unit award, 2025 Equity Incentive Plan, Common Stock

3 terms

restricted stock unit award financial

"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

2025 Equity Incentive Plan financial

"award granted under the Issuer's 2025 Equity Incentive Plan."

Common Stock financial

"security_title: Common Stock, transaction_shares: 16965.0000"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MICHEL GERARD J

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		16,965(1)	A	$0	33,509	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Beta Bionics (BBNX) disclose about MICHEL GERARD J on this Form 4?

Beta Bionics reported that director MICHEL GERARD J received a grant of 16,965 shares of Common Stock as a restricted stock unit award, increasing his directly held position to 33,509 shares after the transaction.

How many Beta Bionics (BBNX) shares were granted to the director?

The director received 16,965 shares of Common Stock. These shares were granted as a restricted stock unit award under Beta Bionics’ 2025 Equity Incentive Plan, rather than purchased in the open market for cash.

What is the total Beta Bionics (BBNX) stake held by the director after the grant?

After the equity grant, director MICHEL GERARD J directly holds 33,509 shares of Beta Bionics Common Stock. This total reflects the addition of 16,965 granted shares reported in the Form 4 filing for May 21, 2026.

Was cash paid for the Beta Bionics (BBNX) shares received by the director?

No cash was paid for these shares. The 16,965 Beta Bionics shares were granted at a reported price per share of 0.0000, indicating a stock-based compensation award rather than an open-market purchase.

Under which plan were the new Beta Bionics (BBNX) shares granted?

The shares were granted under Beta Bionics’ 2025 Equity Incentive Plan. The Form 4 footnote explains that the 16,965 shares represent a restricted stock unit award issued as part of this compensation program for the director.